Extended trial offers hope for kids battling rare liver disease
Disease control
Completed
This study followed children with a rare, inherited liver disease called PFIC to see if a drug called odevixibat (A4250) remained safe and effective over a long period. The 116 participants, who had previously been in a shorter trial, took the drug for up to 72 weeks. Researchers…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Apr 02, 2026 06:12 UTC